A natural extract from orchid plants called Dendrobium officinale polysaccharide (DOP) reduced fat buildup in the liver and improved liver function in rats with fatty liver disease by repairing gut bacteria balance and sealing a leaky intestinal barrier. According to Gram Research analysis of this 2026 study, DOP decreased harmful bacterial toxins that trigger liver inflammation and increased beneficial bacteria that protect intestinal health. However, this research was conducted only in animals and lab cells, so human studies are needed before this treatment could be used in medical practice.
According to Gram Research analysis, a natural extract from orchid plants called Dendrobium officinale polysaccharide (DOP) may help treat fatty liver disease by improving gut bacteria balance. Researchers tested this extract on rats and liver cells, finding that it reduced fat buildup in the liver, repaired the intestinal barrier, and calmed down harmful inflammation. The extract worked by changing which bacteria live in the gut and reducing toxic substances that trigger liver damage. This 2026 study suggests that fixing gut health might be a new way to treat metabolic dysfunction-associated fatty liver disease, a serious condition affecting millions of people worldwide.
Key Statistics
A 2026 research study found that Dendrobium officinale polysaccharide (DOP) markedly reduced hepatic lipid accumulation and restored liver function in rats with metabolic dysfunction-associated fatty liver disease induced by 12 weeks of high-fat diet feeding.
Research published in Frontiers in Pharmacology showed that the orchid extract DOP reduced lipopolysaccharide-enriched Gram-negative bacteria while elevating short-chain fatty acid-producing probiotics in the gut microbiota of rats with fatty liver disease.
In laboratory studies, DOP down-regulated TLR4, MyD88, and NF-kB p65 expression while increasing IκBα levels, effectively suppressing the inflammatory pathway that bacterial toxins use to damage the liver.
The 2026 study demonstrated that DOP repaired intestinal barrier integrity by restoring tight-junction protein expression, preventing the leakage of bacterial lipopolysaccharides into the bloodstream that normally triggers hepatic inflammation.
The Quick Take
- What they studied: Whether a natural plant extract from orchids could treat fatty liver disease by improving gut bacteria and reducing liver inflammation
- Who participated: Male laboratory rats fed a high-fat diet to develop fatty liver disease, plus liver cells grown in a lab and exposed to fatty acids
- Key finding: The orchid extract significantly reduced fat accumulation in the liver, restored normal liver function, and repaired damage to the intestinal barrier that was allowing harmful bacteria toxins to leak into the bloodstream
- What it means for you: This research suggests a potential new treatment approach for fatty liver disease that works through gut health rather than just targeting the liver directly. However, this is early-stage research in animals and lab cells, so human studies are needed before this could become a medical treatment
The Research Details
Researchers created two models of fatty liver disease: one using rats that ate a high-fat diet for 12 weeks, and another using human liver cells exposed to fatty acids in a lab dish. They then treated these models with Dendrobium officinale polysaccharide (DOP), a natural extract from orchid plants, and measured what happened to the liver, gut bacteria, and inflammation markers.
The scientists looked at multiple things to understand how the treatment worked. They examined liver tissue under a microscope to see if fat buildup decreased, tested blood and liver samples for signs of damage, analyzed the types of bacteria living in the rats’ guts using genetic sequencing, and measured inflammatory chemicals that cause tissue damage.
They also studied the specific pathway in liver cells that triggers inflammation, called the TLR4/NF-kB pathway. This pathway is like a alarm system that, when activated by bacterial toxins, tells cells to create inflammation. The researchers measured whether DOP could turn down this alarm system.
This research approach is important because it looks at the whole picture of how fatty liver disease develops. Rather than just treating the liver directly, the study examines how gut bacteria, intestinal health, and the immune system all work together. This systems-based approach may reveal better treatment strategies that address root causes rather than just symptoms.
The study used both animal models and lab cell experiments, which provides multiple lines of evidence. The researchers measured many different outcomes including tissue damage, liver function tests, bacterial composition, and molecular pathways. However, this is early-stage research conducted only in animals and lab cells, not in humans. The sample size for animal studies was not specified in the abstract. Results from animal studies often do not translate directly to humans, so human clinical trials would be needed to confirm these findings.
What the Results Show
The orchid extract (DOP) produced significant improvements in fatty liver disease across multiple measures. In the rat livers, DOP markedly reduced fat accumulation, restored liver function to near-normal levels, and prevented the tissue damage and scarring that typically occurs with this disease.
The extract also dramatically improved gut health. It reduced the population of harmful bacteria that produce lipopolysaccharides (LPS), which are toxic substances that trigger inflammation. At the same time, DOP increased beneficial bacteria that produce short-chain fatty acids, which are compounds that protect intestinal health and reduce inflammation.
Perhaps most importantly, DOP repaired the intestinal barrier, which acts like a fence keeping bacteria and their toxins out of the bloodstream. In fatty liver disease, this barrier becomes leaky, allowing bacterial toxins to enter the blood and reach the liver, where they trigger dangerous inflammation. By sealing this barrier, DOP prevented this toxic leakage.
At the molecular level, the extract turned down the TLR4/NF-kB inflammatory pathway in liver cells. This pathway is like an alarm system that detects bacterial toxins and tells cells to create inflammation. DOP reduced the activation of this alarm system, which explains why inflammation decreased.
The study found that DOP increased expression of tight-junction proteins, which are the molecular structures that hold the intestinal barrier together. This explains how the extract physically repaired the leaky gut. The research also showed that DOP modified the types of metabolites (chemical byproducts) produced by gut bacteria, shifting them toward protective compounds rather than inflammatory ones. Additionally, the extract reduced levels of pro-inflammatory mediators, which are chemical messengers that trigger inflammation throughout the body.
This research builds on growing evidence that gut health plays a central role in fatty liver disease. Previous studies have shown that people with fatty liver disease have different gut bacteria compared to healthy people, and that certain probiotics can help. This study goes deeper by identifying the specific mechanism: the orchid extract works by reshaping gut bacteria, reducing bacterial toxins, repairing the intestinal barrier, and blocking the inflammatory pathway these toxins trigger in the liver. This represents a more complete understanding of how natural compounds might treat this disease.
This research was conducted only in laboratory animals and lab-grown cells, not in humans. Results from animal studies frequently do not translate to humans due to differences in metabolism and physiology. The study did not compare DOP to existing fatty liver disease treatments, so we cannot say whether it would be better or worse than current options. The abstract does not specify how many rats were used or provide detailed statistical analysis. Long-term safety and effectiveness in humans remain unknown. Additionally, the study used a specific type of rat and specific laboratory conditions, so results may not apply to all populations or real-world settings.
The Bottom Line
Based on this research, DOP shows promise as a potential treatment for fatty liver disease, but it is far too early to recommend it for human use. The evidence is moderate strength because it comes from well-designed animal and cell studies, but human clinical trials are essential before any medical recommendations can be made. If you have fatty liver disease, continue following your doctor’s advice regarding diet, exercise, and any prescribed medications. Do not self-treat with orchid extracts based on this single study.
This research is most relevant to people with metabolic dysfunction-associated fatty liver disease (MAFLD), a condition affecting millions worldwide. It should also interest researchers studying natural treatments for liver disease and scientists investigating how gut bacteria influence liver health. People interested in preventive health through diet and natural compounds may find this interesting, though it is not yet ready for practical application. This research is not directly applicable to people with other types of liver disease or those without liver problems.
In the animal models tested, the orchid extract showed effects after 12 weeks of treatment. However, this timeline may not apply to humans. If this treatment ever reaches human trials, it could take 5 to 10 years or more before it becomes available as a medical treatment. Benefits would likely develop gradually over weeks to months rather than days.
Frequently Asked Questions
Can I take Dendrobium officinale extract to treat my fatty liver disease?
Not yet based on current evidence. This 2026 research shows promise in animals and lab cells, but human clinical trials have not been conducted. Talk to your doctor about proven treatments like weight loss, exercise, and dietary changes before considering any supplements.
How does gut bacteria affect fatty liver disease?
Harmful gut bacteria produce toxic substances called lipopolysaccharides that leak through a damaged intestinal barrier into the bloodstream and reach the liver, triggering inflammation and fat accumulation. Beneficial bacteria produce protective compounds that reduce this damage.
What is metabolic dysfunction-associated fatty liver disease?
MAFLD is a condition where fat builds up in liver cells, usually linked to obesity, diabetes, or metabolic problems. It can progress to liver damage and scarring if untreated. It affects millions of people worldwide and is becoming more common.
When will Dendrobium officinale be available as a treatment?
This is unknown. The research is in early stages with only animal and lab studies completed. If human trials begin soon, it could take 5 to 10 years or more before any treatment becomes available, assuming it proves safe and effective in people.
What can I do now to improve my fatty liver disease?
Evidence-based approaches include losing 5 to 10 percent of body weight, exercising 150 minutes weekly, reducing refined carbohydrates and added sugars, increasing fiber intake, and limiting alcohol. Work with your doctor to monitor liver function through blood tests.
Want to Apply This Research?
- Users with fatty liver disease could track liver function markers (ALT and AST enzymes from blood tests) every 3 months, along with waist circumference and weight, to monitor disease progression. They could also log dietary fat intake and fiber consumption to correlate with any changes in liver health markers.
- While awaiting human studies on DOP, users could implement evidence-based lifestyle changes: increase soluble fiber intake from oats, beans, and vegetables to feed beneficial gut bacteria; reduce refined carbohydrates and added sugars; increase physical activity to 150 minutes per week; and maintain a healthy weight. The app could provide reminders and track these behaviors.
- Set up quarterly check-ins to review liver function blood tests with a healthcare provider. Track weight, waist circumference, and dietary patterns monthly. Monitor energy levels and digestive health weekly. Once human trials of DOP begin, users could discuss participation with their doctor and track any clinical trial results through the app.
This article summarizes early-stage research conducted in animals and laboratory cells. These findings have not been tested in humans and should not be used to guide personal medical decisions. Dendrobium officinale polysaccharide is not approved by the FDA for treating fatty liver disease or any other condition. If you have fatty liver disease or suspect you may have it, consult with a qualified healthcare provider for proper diagnosis and evidence-based treatment options. Do not replace prescribed medications or medical advice with supplements or natural extracts based on this research. Always inform your doctor about any supplements you are considering.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.